Pharvaris Stock (NASDAQ:PHVS)
Previous Close
$19.01
52W Range
$15.37 - $33.00
50D Avg
$21.12
200D Avg
$20.11
Market Cap
$1.06B
Avg Vol (3M)
$87.16K
Beta
-3.15
Div Yield
-
PHVS Company Profile
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients and is under Phase 1 clinical trial. It operates in the Netherlands, Switzerland, and the United States. The company was incorporated in 2015 and is based in Leiden, the Netherlands.
PHVS Performance
Peer Comparison
| Ticker | Company |
|---|---|
| STOK | Stoke Therapeutics, Inc. |
| TYRA | Tyra Biosciences, Inc. |
| JANX | Janux Therapeutics, Inc. |
| PMVP | PMV Pharmaceuticals, Inc. |
| ANTX | AN2 Therapeutics, Inc. |
| IKNA | Ikena Oncology, Inc. |
| MLYS | Mineralys Therapeutics, Inc. |
| GLUE | Monte Rosa Therapeutics, Inc. |
| DSGN | Design Therapeutics, Inc. |
| MNOV | MediciNova, Inc. |
| RZLT | Rezolute, Inc. |
| HOWL | Werewolf Therapeutics, Inc. |
| PEPG | PepGen Inc. |
| ANEB | Anebulo Pharmaceuticals, Inc. |
| MOLN | Molecular Partners AG |